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OBJECTIVES This study assessed coronary artery endothelial function in patients with hypercholesterolemia
before and after lipid lowering, using quantitative angiography to examine the acetylcholine
(Ach) response along the entire analyzable vessel.
BACKGROUND Lipid lowering reverses endothelial dysfunction, but whether improvement occurs only in
some segments and not others has not been established. Statistical correlation of improve-
ment with specific lipid moieties remains undefined.
METHODS Quantitative angiography was performed after Ach (1026, 1025, 1024M) in 29 patients with
coronary atherosclerosis before and 18 6 5.2 months after lipid-lowering treatment (statins,
bile sequestrant resins). Standard lipid moieties and markers of oxidized low density
lipoprotein (LDL) (immunoglobulin G and M autoantibody titers to malondialdehyde-LDL,
E06 epitope) were measured serially.
RESULTS Pre-treatment of the vessel diameters at control and with 1026M, 1025M and 1024M Ach
were 2.108 6 0.085, 2.086 6 0.087, 2.069 6 0.084 and 1.963 6 0.097 mm (M 6 SE),
respectively, and increased at follow-up to 2.139 6 0.094, 2.119 6 0.086, 2.127 6 0.084 and
2.080 6 0.085 mm (p , 0.0001). Improvement in the most constricted and modest
declination in the more dilated segments were observed. Change in the E06 and Apolipopro-
tein A-1 titers correlated with improved vasomotion (p 5 0.027 and 0.005, respectively). The
pre- and post-treatment levels of the E06 epitope, as well as the post-treatment IgM
autoantibody titer to MDA-low density lipoprotein, also correlated (p , 0.028, , 0.001 and
p , 0.004, respectively).
CONCLUSIONS Drug treatment reverses endothelial dysfunction, but the effect is heterogeneous. Most
coronary segments show enhancement, while others show declination of dilation, underscor-
ing the importance of assessing the entire analyzable artery. Improvement in vasomotion
correlates most significantly with markers of plasma-oxidized low-density lipoprotein. (J Am
Coll Cardiol 2001;37:766–74) © 2001 by the American College of Cardiology
After lipid lowering, a reversal of coronary artery endothelial
dysfunction in patients with hypercholesterolemia has been
reported (1–5), suggesting that amelioration of constrictive
vasomotion may help reduce coronary events. These studies
focused on limited segments of the coronary artery and did
not account for the heterogeneity of response to acetylcho-
line (Ach), such that normal vasodilatation and paradoxical
vasoconstriction may occur in different segments of the
same artery (6,7). Furthermore, it has not been defined
whether improvement in coronary reactivity is predicted by
absolute pre- or postlipid-lowering plasma levels of lipid
moieties or the magnitude of their change during drug
treatment.
In this study we examined the changes with lipid lower-
ing in coronary vasomotor response to Ach using serial
quantitative angiography with comprehensive analysis of a
number of segments of the same artery. A correlation was
then made between the change in vasomotor response and
pre- and post-treatment serum lipid moieties.
METHODS
Patient selection, demographics and characteristics. Pa-
tients with stable angina, a mildly positive exercise treadmill
test and hypercholesterolemia (serum total cholesterol .200
mg/dl) were enrolled in a protocol approved by the Inves-
tigational Review Board of the University of California, San
Diego, School of Medicine and the Veterans Affairs Med-
ical Center, San Diego. Individuals with a recent myocardial
infarction, unstable or variant angina, congestive heart
failure or severe peripheral vascular disease were excluded.
All patients had mild atherosclerotic luminal irregularities
(,50% obstructive) of the artery studied.
Lipid-lowering regimen. After baseline lipid moieties and
coronary arteriography had been performed, enrollees were
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instructed in the Step I diet of the National Cholesterol
Education Program and prescribed a graduated dose of an
HMG coenzyme A inhibitor (lovastatin) aimed at reducing
their total and low density lipoprotein (LDL) cholesterol to
below 200 mg/dl and 100 mg/dl, respectively. Seven of 29
patients were given a bile-acid sequestrant subsequently.
Follow-up angiography was performed once the patient’s
total and LDL cholesterol had each reached a plateau (three
successive determinations) on lovastatin of 40 mg/day or
greater. If a patient smoked cigarettes, he/she was encour-
aged to stop although cessation was not required for a
patient to remain in the study.
Lipoprotein quantification. Blood samples were collected
monthly. Lipid measurements were as described in the
Lipid Research Clinic Manual of Laboratory Operations
(8). The inter-assay coefficient of variation was 0.8% for
total cholesterol, 1.7% for total triglycerides and 2.4% for
high density lipoproteins (HDL) cholesterol. Apolipopro-
tein (Apo)-A1, Apo-B as well as lipoprotein (a) were
determined on a Roche-COBAS BIO instrument using
appropriate INCSTAR kits and standards.
Immunoglobulin G and M (IgG, IgM) titers of autoan-
tibodies to malondialdehyde-LDL (MDA-LDL) in human
plasma were determined using modifications of a previous
assay (9). Malondialdehyde-LDL was produced by sequen-
tial ultracentrifugation of healthy human donor plasma in
the presence of high concentrations of antioxidants (10).
The degree of modification of the lysine residues of Apo-B
was determined by the trinitrobenzenesulfonic acid assay
(11,12) and was consistently above 75%. Data were ex-
pressed in relative luminescence units (RLU) per 100 ms.
Samples were run in a single assay; the intra-assay coefficient
of variation varies from 8% to 10%.
The murine monoclonal antibody E06 recognizes an
oxidized phospholipid epitope that is on LDL as it under-
goes oxidation. Thus, it is a sensitive index of early stages of
oxidized LDL (ox-LDL) (13,14). The E06 epitope concen-
tration in Apo-B 100 containing particles was measured by
a chemiluminescence enzyme immunoassay (14). This assay
was based on two monoclonal antibodies, an antihuman
Apo B-100 antibody, MB47, and a biotin-labeled antioxi-
dized phospholipid antibody, E06. The amount of Apo-B-
100 containing particles bound to the MB47 coated plates
was measured by using another biotin-labeled antihuman
Apo-B-100 monoclonal antibody, MB24, to normalize the
bound LDL of each sample. These two anti-Apo-B-100
antibodies bind to distinct Apo-B-100 epitopes. Data were
given for absolute levels of E06 bound per well
(RLU/100 ms) or as a ratio of E06/MB24. Because each
MB24 antibody binds once to each LDL, the E06/MB24
ratio yields an estimate of E06 epitopes/LDL. All samples
were run in a single chemiluminescence enzyme immuno-
assay; the intra-assay coefficient of variation was 6%.
Angiographic protocol. All vasodilator therapy was dis-
continued 48 h before the angiographic procedure (6). After
diagnostic angiography, an end-hole 3F-infusion catheter
was placed into the proximal segment of the coronary artery
to be studied. Atrial pacing at 80 beats/min was initiated
from the right atrium. Biplane coronary angiography was
performed at control and during serial, 3-min infusions of
Ach at 1026M, 1025M and 1024M; assuming a coronary
flow of 80 ml/min, this would yield intracoronary Ach
concentrations of 1028M, 1027M and 1026M, respectively.
For each injection, 9 ml of Omnipaque 350 (Winthrop-
Breon Laboratories, New York) at 6 ml/s were injected
using a Medrad Mark IV injector (Medrad Inc., Pittsburgh,
Pennsylvania).
Quantitative coronary angiography. In any given patient,
all images were acquired at identical X-ray gantry, table
height and source-to-image intensifier distances. Projec-
tions chosen displayed the maximum length of the artery
and minimized foreshortening and vessel overlap. The
guiding catheter was imaged unopacified, and the catheter
tip was later measured using electronic calipers to calibrate
the magnification for each injection. End-diastolic cine
frames were digitized at a resolution of 512 3 512 pixels, 8
bits, at end-diastole using a 35 mm SONY (Tokyo, Japan)
SME 3500 Cine Video System interfaced to an Imaging
Technology, Inc. (Bedford, Massachusetts) 150 Series video
digitizer and a Silicon Graphics, Inc. (Mountainview, Cal-
ifornia) 4D/380/VGX computer. Vessel edges were deter-
mined by an automatic edge detection routine (15) with
potential for manual override. The vessel centerline and
diameters perpendicular to this centerline were calculated
and interpolated as previously described (6). The arterio-
gram was partitioned into successive 3 mm segments, and
the diameters in each segment were then averaged, Figure 1.
Our routines ensured the geometric identity, or very near
correspondence, of segments that were compared as part of
the vasomotion analysis.
Statistical analysis. AVERAGE OF SEGMENT DATA PER PA-
TIENT. Data were analyzed as a two-level, repeated mea-
sures analysis of variance (SuperANOVA 1.11, Abacus
Concepts, Inc., Berkeley, California) with the first level
comparing responses at each dose of Ach and the second
level comparing results at baseline to those after cholesterol
lowering. A statistical contrast was constructed before data
analysis in which the single comparison was the combined
Abbreviations and Acronyms
Ach 5 acetylcholine
Apo 5 apolipoprotein
eNOS 5 endothelial nitric oxide synthase
HDL 5 high density lipoprotein
HLM 5 hierarchical linear model
IgG 5 immunoglobulin G
IgM 5 immunoglobulin M
LDL 5 low density lipoprotein
LRfx 5 lipid reduction effect
MDA 5 malondialdehyde
NO 5 nitric oxide
ox-LDL 5 oxidized low density lipoprotein
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change in the vessel diameter values between baseline and
follow-up studies (cell weights 6 0.25 for control, Ach
1026M, 1025M and 1024M for absolute vessel diameter
analysis; cell weights 6 0.33 for Ach 1026M, 1025M and
1024M for absolute change [D] and percentage change
[%D] diameter analysis). Because a single comparison was
constructed a priori in each contrast analysis, a p value
,0.05 was considered significant.
Segment data. Analysis of segment data, using a standard
repeated measures analysis of variance, is confounded by an
unequal number of segments nested within each patient and
the potential for intra-class correlation of these segments in
any given patient. Some authors have approached this type
of problem by use of a general linear model of intra-class
correlation (16). This approach was not suitable here where
repeated measures of coronary vasomotion, before and after
lipid lowering, were made in each patient. Thus, we applied
a hierarchical linear model (HLM) that adjusts variances for
patient differences, segment differences and, finally, re-
peated measures (17). For hierarchical analysis, we used
HLM v. 4.01 (Bryk, Raudenbush & Congdon, Scientific
Software International, Chicago, Illinois).
Correlation with lipid moieties. The HLM indicated that
58% of the high-level variance in this study was between
patients and 42% was between coronary artery segments
within patients. Both variance components were statistically
significant. Because significant variance was at the segmen-
tal level, the effects of lipid moieties on change in coronary
vasomotion were developed in level-3 HLM models using
nine measured lipid moieties (total cholesterol, LDL, HDL,
lipoprotein (a), Apo-A-1, Apo-B, IgM autoantibody, IgG
autoantibody and the E06 epitope). Three separate models
were used to analyze the influence of the absolute pre-, the
absolute post-, and the change (D) in lipid moieties. All
possible covariates were included so as to obtain a value for
m0, the estimated residual level-3 error variance. Additional
analyses were then run, each one successively excluding one
of the set of covariates. The proportion of variance ac-
counted for by a particular covariate was taken as:
Proportion of variance 5
mo for the reduced model 2
mo for the inclusive model
mo for the reduced model
Only covariates that accounted for at least 5% of the residual
error variance were accepted back into the model until the
excluded covariates in aggregate accounted for no more than
10% of the residual variance.
Figure 1. Composite image of a left anterior descending coronary artery. Algorithm-derived edges, the calculated vessel centerline, vessel segments and
sequential diameters are displayed. Branch points are used for interpolation of diameters (6). pt 5 point.
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RESULTS
Patient attributes and lipid moieties. Forty patients were
initially enrolled in the study; seven patients refused
follow-up angiography, and in three patients Ach was not
given at follow-up, because of progression of coronary artery
disease. One patient in whom one dose of Ach was infused
was also excluded from final analysis.
The final cohort consisted of 27 men and 2 women, with
a mean age of 59.5 6 8.3 years (M 6 SD, range 44 to 73
years). Seven patients were current cigarette smokers, and
17 were former smokers; five had never smoked. Fifteen
patients had hypertension, and two had diabetes mellitus.
Seven patients were on antioxidant vitamins (Vitamin E, C
or both) throughout the protocol. The left anterior descend-
ing artery was studied in 24 patients, and the left circumflex
artery in five patients. The lipid moiety values, before and
after lipid lowering, are given in Table 1.
Quantitative coronary dimensions. AVERAGE SEGMENT
RESPONSES PER PATIENT. The mean vessel diameters dur-
ing the series of infusions were significantly greater at
follow-up than they were at baseline (n 5 29, p , 0.0001,
Fig. 2, panel A, Table 2). The response to Ach was
calculated as the change in vessel diameter (D diam) from
control infusion for each segment (negative numbers indi-
cate constriction), then averaged for each patient (Fig. 2,
panel B, Table 2). The response to Ach was also calculated
as the percent change in vessel diameter from control
infusion for each segment (negative numbers indicate con-
striction), then averaged for each patient (Fig. 2, panel C,
Table 2). Vasoconstriction induced by the Ach infusions
was significantly decreased after lipid lowering (n 5 29, p ,
0.05 vs. before lipid lowering).
Hierarchical linear model. In the hierarchical model, the
lipid reduction effect (LRfx) is taken as the arithmetical
difference between the baseline and follow-up vasomotion
response (D diam) to each dose of Ach. The effect of lipid
lowering is then assessed in terms of the linear relationship
between LRfx and the drug dosage of Ach.
In a two-level analysis of covariance, patients were the
grouping variable, the mean LRfx for each patient was the
dependent variable and dosage of Ach the covariate. The
intercept, which is the mean LRfx adjusted across subjects
for Ach 1025M, was not significantly different from zero
(coefficient 5 0.0364; t[28] 5 0.98; p . 0.3). The common
slope estimate, however, was significantly greater than zero
(coefficient 5 0.0438; t[28] 5 2.05; p , 0.05), indicating a
significant dosage effect and, therefore, a significant impact
of lipid reduction on arterial vasomotion. The variance in
the intercept, which indicates the variability among patients
in their responses to treatment, was also significant (m0j 5
0.0317; c2[28] 5 128.8; p , 0.001). These findings confirm
that, after hypolipidemic therapy, coronary dimensions, on
average, manifest less vasoconstriction in response to pro-
gressive doses of Ach.
In a three-level analysis (analysis of covariance), both
patient-level and segment-level effects are incorporated into
a single model: level 1 is the assay level, with dosage of Ach
as a covariate; level 2 is the segment level, and level 3 is the
patient level. The dependent variable is LRfx, and the dose-
response slope is constrained to a homogeneous, fixed
estimate by setting the random effects in the slope equations
(i.e., r1jk and u10k) to zero. Although the slope coefficient
was smaller than that estimated from the patient level, it was
much more reliable (coefficient 5 0.0287; t 5 3.90; p ,
0.001). The variance in the intercept, which indicates the
variability among segments and among patients in their
responses to treatment, was also significant (for segments,
variance 5 0.0270; c2 [553] 5 827.8; p , 0.001; for
patients variance 5 0.0361; c2 [28] 5 434.1; p , 0.001).
Thus, the incorporation of segmental, as well as average
patient, information into the statistical model uncovered
more fully the significant effect of lipid lowering on coronary
vasomotion.
Heterogeneity of change in vasomotor response. A het-
erogeneous pattern of response (improvement in endothelial
function in at least one segment and declination in endo-
Table 1. Effects of Lipid-Lowering Treatment on Lipid Moieties
Lipid Moiety Prelipid Lowering Postlipid Lowering Significance
Total cholesterol 240.0 6 28.7 (mg/dl) 178.7 6 24.2 (mg/dl) p , 0.0001
LDL 161.9 6 27.3 (mg/dl) 103.1 6 22.2 (mg/dl) p , 0.0001
HDL 49.0 6 9.4 (mg/dl) 52.4 6 11.3 (mg/dl) p , 0.03
Lp(a) 29.2 6 24.6 (mg/dl) 30.6 6 25.6 (mg/dl) p 5 0.37
Apo-A-1 149.2 6 21.4 (mg/dl) 145.9 6 19.5 (mg/dl) p 5 0.28
Apo-B 114.9 6 14.8 (mg/dl) 89.8 6 13.3 (mg/dl) p , 0.0001
IgM autoantibodies to
MDA-LDL
155,426 6 52,524 (RLU/100 ms) 154,040 6 48,686 (RLU/100 ms) p 5 0.85
IgG autoantibodies to
MDA-LDL
31,841 6 17,649 (RLU/100 ms) 36,784 6 18,181 (RLU/100 ms) p 5 0.20
Absolute E06 epitope
assay
4,005 6 2,829 (RLU/100 ms) 6,275 6 8,187 (RLU/100 ms) p 5 0.08
E06/MB24 0.027 6 0.019 (RLU/100 ms) 0.044 6 0.058 (RLU/100 ms) p 5 0.07
Apo-A-1 5 apolipoprotein A-1; Apo-B 5 apolipoprotein B; E06 5 E06 autoantibody to epitope of oxidized LDL; HDL 5
high density lipoprotein; IgG 5 Immunoglobin G autoantibody to oxidized LDL; IgM 5 Immunoglobin M autoantibody to
oxidized LDL; LDL 5 low density lipoprotein; Lp(a) 5 lipoprotein (a); MDA 5 malondialdehyde; T Chol 5 total cholesterol.
769JACC Vol. 37, No. 3, 2001 Penny et al.
March 1, 2001:766–74 Reversal of Endothelial Dysfunction: Importance of Ox-LDL
thelial function in at least one segment) was noted in 25 of
the 29 patients at the maximum dose of Ach. Moreover, 20
of the 29 patients had vessel segments that both improved
and worsened by 10 or more percentage points (Fig. 3).
Also, we ranked the segments from worst to best for each
patient (as previously mentioned) and adjusted for the
disparate number of segments per patient by normalization
on a scale from 0 (most constricted) to 100 (most dilated),
then analyzed by decile (Fig. 4). At baseline, the most
constricted decile demonstrated a mean change of 218%
from control, and the most dilated decile demonstrated a
change of 16%. At follow-up, with baseline decile rankings
maintained, the range had narrowed, and the slope had
flattened due to improved function in the most constricted
segment deciles and some declination of function in the
segment deciles, which dilated at baseline. These changes in
Figure 2. Changes in vessel dimension and vasomotor response to successive Ach infusions are shown as the average of per patient means (n 5 29). (A)
Plot of mean vessel diameter in mm at control and after Ach infused at 1026 to 1024M. Baseline values (M 6 SE) are shown as closed circles/solid line;
values from follow-up study after cholesterol lowering are shown as open squares/dashed line. (B) Plot of mean change (in mm) in vessel diameter from
control upon Ach infusion at graded doses (M 6 SE). (C) Plot of mean percent change in vessel diameter from control upon Ach infusion at graded doses
(M 6 SE). Ach 5 acetylcholine. Solid circle 5 baseline; Shaded square 5 follow-up.
770 Penny et al. JACC Vol. 37, No. 3, 2001
Reversal of Endothelial Dysfunction: Importance of Ox-LDL March 1, 2001:766–74
response to Ach after cholesterol lowering did not predom-
inate in any given region of the artery.
Correlation of improvement in vasomotion with lipid
moieties. The lipid-lowering E06 autoantibody (as a dif-
ference and also as an absolute before or after lipid-lowering
variable) showed in aggregate the most powerful influence
on improvement in vasomotion. The most potent variable
was the postlipid-lowering E06 autoantibody level, which
accounted for 22.1% of the variance in vasomotion (p ,
0.007). The absolute postlipid-lowering IgM autoantibody
to oxidized LDL and the change with Apo-A-1 also
correlated significantly with the change in coronary vaso-
motion.
By simple linear regression, no statistically significant
correlation (p , 0.05) was found between the pre–lipid
lowering Ach response and any one of the pre-treatment
Table 2. Assessment of Coronary Artery Acetylcholine
Responses, Pre- and Postlipid Lowering
Drug State
Prelipid
Lowering
Postlipid
Lowering
Absolute Diameters (mm)
Control 2.108 6 0.085 2.139 6 0.094
Acetylcholine 1026M 2.086 6 0.087 2.119 6 0.086
Acetylcholine 1025M 2.069 6 0.084 2.127 6 0.084
Acetylcholine 1024M 1.963 6 0.097 2.080 6 0.085
Change in Diameter (D mm)
DAcetylcholine 1026M 20.022 6 0.021 20.020 6 0.029
DAcetylcholine 1025M 20.038 6 0.030 20.012 6 0.036
DAcetylcholine 1024M 20.144 6 0.047 20.059 6 0.041
Percentage Change in Diameter (%)
%DAcetylcholine 1026M 20.58 6 1.06 20.44 6 1.32
%DAcetylcholine 1025M 21.24 6 1.70 0.31 6 1.53
%DAcetylcholine 1024M 26.74 6 2.73 21.67 6 1.94
2 5 vasoconstriction.
Figure 3. Heterogeneity of vasomotor response after cholesterol lowering demonstrated as the interval change of response of all segments to Ach 1024M
grouped by patient number. See text for further discussion. Ach 5 acetylcholine.
Figure 4. Plot of percentage change in segment diameter versus control
(vertical axis) ranked by decile from the most constricted to the most
dilated (horizontal axis). Data for infusion of Ach 1024M presented. Note
that the most constricted segments improved after lipid lowering while
those that dilated showed less dilation or mild constriction. See text for
discussion. Ach 5 acetylcholine. Open square 5 prelipid-lowering; closed
circle 5 postlipid-lowering.
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lipid moieties. No significant correlation was found between
coronary vasomotion improvement and the nominal vari-
ables of smoking, hypertension, diabetes mellitus or use of
antioxidant vitamins.
DISCUSSION
We report here the results of a comprehensive coronary
artery segmental analysis in patients with hypercholesterol-
emia treated with cholesterol-lowering agents. While the
significant improvement in endothelial function corrobo-
rates previous studies (1–5), assessment of the entire ana-
lyzable artery suggests that the phenomenon may be more
complex than indicated by investigations that focused on
selected coronary segments.
Our quantitative angiographic methodology differs from
previous lipid-lowering studies in these respects: 1) a num-
ber of contiguous segments are analyzed in the same patient;
2) an interpolation routine ensures correspondence of seg-
ments analyzed before and after Ach and before and after
lipid lowering; (6) and 3) our statistical analysis incorporates
a calculation of data variance at both the patient and
segmental levels (17). This latter approach uses the statis-
tical power inherent in analyzing several segments in each
patient while accounting for nesting of segments within
patients, the repeated measures for analysis of coronary
vasomotion and the use of several doses of Ach in testing
endothelial integrity.
Heterogeneity of vasomotor response to cholesterol-
lowering. The response to cholesterol lowering was depen-
dent upon the initial response of the segment to Ach, with
a pattern of improved vasomotion in the most constricted
segments from the baseline study and a declination of the
most dilated segments. This pattern was incremental
throughout the artery when baseline responses to Ach were
ranked by decile (Fig. 4). The finding of most marked
improvement in the most constricted of selected segments
of the control study was also described in the work of
Anderson et al. (3) and Treasure et al. (2). This pattern also
parallels the results of the MARS trial (18), a study of
changes in angiographically defined coronary stenoses after
cholesterol lowering. Here there was a small degree of
regression of stenosis in those patients in the test group (on
lovastatin) compared with the placebo group. Subset anal-
ysis revealed that lesions .50% stenotic on the baseline
study showed regression (improvement), while lesions
,50% at baseline demonstrated progression of stenosis
severity (worsening) at follow-up.
Sources of heterogeneity. STATISTICAL. The observed
pattern may be due to a regression toward the mean, where
extreme outlying points (both the most Ach constricted and
dilated segments, arbitrarily chosen for quantification from
a normal distribution) fall closer to the central tendency (the
average) when resampled and quantified at follow-up. The
segmental vasomotor responses also may be constrained by
limits of maximal vasoconstriction (i.e., 100%) and vasodi-
lation. Thus, the variability inherent in quantitative analysis
may result in less marked mean change at follow-up in
segments that exhibit extreme changes upon initial assess-
ment, as there can be more underestimation than overesti-
mation of the subsequent response due to these anatomic
constraints.
Pathophysiologic. The heterogeneous response to lipid
lowering also may be due to pathophysiologic mechanisms.
An obvious source is the segmental distribution of athero-
sclerosis. Another source could be a nonuniform decrease by
lipid lowering in the oxidative milieu of the endothelium
and subendothelium. This uneven effect may lead to a
variable decrease in sensitivity of the muscarinic receptors of
the vascular smooth muscle cells to the effect of Ach. This
change could have the most marked effect on the most
abnormal vessel segments, resulting in reversal of vasocon-
striction, and less effect on the segments that were more
normal at the outset and, thus, were not affected predomi-
nantly by direct muscarinic stimulation.
Variability in segmental response to lipid lowering may
reside in other factors that control vasomotor tone, includ-
ing shear stress, catecholamines, bradykinin, endothelin-1
and platelet-derived products (19). Isolation of these factors
in a clinical investigation is difficult and was not attempted
in this protocol. Nevertheless, assuming that coronary blood
flow remains constant, one can deduce that basal vasodila-
tion would serve to reduce vessel curvature and diminish
shear forces along the wall and in surrounding segments
(20,21). This might explain, in part, the reduced dilation
with lipid lowering in those segments that initially mani-
fested a more normal response to Ach challenge.
Improvement of the vasomotor response to lipid lowering.
The current evidence is compelling that lipid lowering is
associated with a net improvement in coronary artery
dimensions and the vasomotor response to a drug that
stimulates the endothelial-derived relaxation factor, nitric
oxide (NO). Several explanations for this improvement
appear tenable: 1) reduced potentiation of factors that
inactivate endothelial-derived relaxation factor, such as
oxidized LDL or its by-products (22–25), 2) an effect of
antioxidants (9) or 3) an up-regulation of endothelial nitric
oxide synthase (eNOS) as a direct effect of drug treatment
(26).
Ox-LDL. Markers of ox-LDL correlated significantly in
this study with the response to Ach. Other investigations
support an important role for ox-LDL in endothelial
dysfunction. Oxidized LDL adversely affects NO produc-
tion and activity in vascular ring preparations (27,28) in
endothelial cells (22,23) and in platelets (24). Anderson et
al. measured the susceptibility of LDL to oxidation using
the lag phase of conjugated diene formation induced by
Cu11 and found that the vasodilator response to Ach
related significantly to the susceptibility of LDL to oxida-
tion (25). A reported significant (p 5 0.023) correlation
between oxidized LDL levels and dipyridamole-induced
coronary flow reserve, as measured by positron emission
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tomography, supports this conclusion (29). Tamai et al. (30)
reported improved Ach-induced vasodilatation in the fore-
arm with acute LDL apheresis. In these subjects there was
a significant inverse correlation between plasma LDL (as
well as oxidized LDL) and the maximal concentration in
the venous effluent of the forearm of NOx (a rapidly
oxidized, in vivo product of NO) measured before and after
Ach administration. Other reports suggest a relationship
between autoantibodies of ox-LDL and progression of
atherosclerosis (9) as well as risk of myocardial infarction
(31).
In the E06 assay utilized here, the murine monoclonal
antibody recognizes an oxidized phospholipid epitope on
ox-LDL. The number of E06 epitopes per LDL particle
was related significantly to the severity of endothelial
dysfunction and in the post-therapy study was the single
most powerful independent risk factor, accounting for fully
22% of the variance. Because this is a direct assay for an
epitope of early stages of ox-LDL, it provides further strong
evidence that oxidation of LDL is an important variable
influencing abnormal coronary vasomotion in patients with
atherosclerosis.
Antioxidants. There is also evidence that ascorbic acid, a
vitamin antioxidant, reverses endothelial dysfunction in
patients with coronary heart disease (32) and probucol, a
potent antioxidant as well as lipid-lowering agent, improves
endothelial dysfunction over and above that produced by
lipid lowering itself (3). Other investigations, however, have
shown no improvement in endothelial dysfunction by either
a panel of antioxidant vitamins or superoxide (33). We
found no significant correlation between improvement in
response to Ach and patient use of antioxidants.
Up-regulation of eNOS. Lauf et al. (26) reported that
inhibition of endothelial HMG CoA reductase by simvista-
tin and lovastatin directly upregulates eNOS, predomi-
nantly by post-transcriptional mechanisms. This would
suggest that lipid lowering might not be integral to the
salutary effect of statins. It may also help explain either the
absence or the lack of a strong statistical correlation between
changes in serum levels of either total cholesterol or LDL
and the improvement in vasomotor response to Ach.
Study limitations. This study examined the vasomotor
response of a single main artery in the total coronary arterial
tree. A different conclusion might be drawn if all branches
were examined in the territory of the artery into which Ach
was infused or if all coronary arteries were examined.
However, the accuracy of quantitative angiography is sub-
optimal when very small vessels are measured (34). In our
own phantom studies, the accuracy and precision of mea-
surement declines significantly when conduits are 0.6 mm or
less in diameter (35). Likewise, optimal angiographic pro-
jection for all subbranches is technically challenging, even
when biplane views are used. Infusion of Ach in all coronary
arteries has not been performed due to the need for separate
left and right coronary infusions.
Conclusions. We conclude that, in patients with hyper-
cholesterolemia, lipid-lowering therapy improves endothe-
lial function and causes a small, but measurable, dilation of
basal coronary artery dimensions. Nevertheless, the response
to Ach is complex, with a heterogeneous pattern of in-
creased diameter in some segments and reduction in others.
This pattern underscores the importance of inclusion of the
entire analyzable artery when studying coronary vasomo-
tion. Investigations that focus on responses from isolated
segments of an artery, especially serial studies that include
only segments that demonstrate a visually detectable re-
sponse to Ach at baseline, would be vulnerable to erroneous
or exaggerated conclusions. Despite the variability in seg-
mental vasomotion to Ach challenge, the aggregate coro-
nary artery response correlated highly with markers of
plasma ox-LDL, reinforcing its pathogenetic role in the
endothelial dysfunction associated with atherosclerosis.
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